News | November 13, 2023
Marksans Pharma posts Q2 FY24 consolidated PAT at Rs. 82.7 Cr
US business grew by +12.8% YoY
US business grew by +12.8% YoY
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Dr. Reddy’s maintains that the allegations against it lack merit and will vigorously defend the litigation
The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23
The collaboration brings a seamless digital experience to more formulators worldwide
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
Total transaction value of the divestment is Rs. 3,660 million
PhytoSquene now available for clinical and commercial use
Lack of technology transfer stands out as a formidable barrier
This product will be manufactured at Lupin’s Pithampur facility in India
Subscribe To Our Newsletter & Stay Updated
